Koene R A, Gerlag P G, Jansen J L, Moulijn A C, Skotnicki S H, Debruyne F J, Kunst V A, Geerdink P, Wijdeveld P G
Proc Eur Dial Transplant Assoc. 1977;14:401-6.
A 19-year old male with severe haemophilia A (factor VIII activity less than 1%) developed terminal renal insufficiency and was subsequently dialysed via an external arteriovenous shunt for one year. To prevent bleeding he received cryoprecipitate (2000-2500 units of factor VIII) three times a week during dialysis. After one year of uneventful dialysis he received a kidney graft from a cadaver donor that was matched for the B locus antigens. During the first two weeks after transplantation his factor VIII level was kept at approximately 70% by daily cryoprecipitate infusions. Thereafter he was free from bleeding at a level of 20% with prophylactic cryoprecipitate treatment (1000 units 3 times a week). He was discharged from the hospital five weeks after transplantation with excellent renal function (ECC 75 ml/min). No rejection crisis occurred. His factor VIII requirements remained unchanged after transplantation, indicating that the human kidney does not substantially contribute to the production of clotpromoting factor VIII.
一名19岁重度甲型血友病男性（因子VIII活性低于1%）出现终末期肾功能不全，随后通过体外动静脉分流进行了一年的透析。为预防出血，他在透析期间每周接受三次冷沉淀（2000 - 2500单位因子VIII）。经过一年平稳的透析后，他接受了一名与B位点抗原匹配的尸体供者的肾脏移植。移植后的头两周，通过每日输注冷沉淀，他的因子VIII水平维持在约70%。此后，在预防性冷沉淀治疗（每周3次，每次1000单位）下，因子VIII水平为20%时他未再出血。移植五周后他出院，肾功能良好（内生肌酐清除率75 ml/分钟）。未发生排斥反应。移植后他对因子VIII的需求保持不变，这表明人肾对促凝血因子VIII的产生没有实质性贡献。
